ClinicalTrials.gg
Not yet recruitingNCT07455084Updated Oct 16, 2026

A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults

A Phase 1 interventional study of 14C-SEP-380135 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Not yet recruiting at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Updated Oct 16, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. — 3 open to participants now, 4 under way, 3 of them phase 3. Schizophrenia · Otsuka Holdings Co., Ltd..

Planned enrollment
108th of 111
8 · median 125
Started
2026
the only one that year
Phase 1
34 of 120
1 open now
Registered
119th of 120
by date

Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 108th largest by planned enrollment of the 111 interventional ones that give a count, is the only one that started in 2026, is one of 34 in phase 1, and was the 119th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

3 of the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., or all of them as a file.
02

Study summary

The purpose of the present trial is to obtain information on the absorption, distribution, metabolism, excretion and pharmacokinetics (PK) of 14C-SEP-380135 and its metabolites following a single oral dose.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Mental Health Conditions, Schizophrenia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) between 18.0 and 32.0 kilograms per square meter (kg/m²).
  2. In good overall health, based on:

    1. Medical history
    2. Physical examination
    3. Neurological examination
    4. Vital signs
    5. (ECG)
    6. Blood and urine tests (serum chemistry, hematology, urinalysis, serology)
  3. Regular daily bowel movements (at least one per day) for 30 days before Day -2.
  4. Ability to provide written and follow all study instructions.
  5. Has a stable living situation at screening and agrees to return to a similar living arrangement after the in-clinic stay.

Exclusion criteria

Exclusion Criteria:

  1. Have taken an drug within 30 days or 5 half-lives, if known, (whichever is longer) prior to screening.
  2. Have had prior exposure to SEP-380135.
  3. Are currently participating in another clinical trial.
  4. Attempted suicide within 12 months prior to screening.
  5. A history of sick sinus syndrome, any degree of atrioventricular block, Heart attack (myocardial infarction), heart failure ( Class II-IV), cardiomyopathy, pulmonary congestion, cardiac arrhythmias, prolonged , congenital long QT syndrome, family history of long QT, or moderate to severe hypokalemia. A participant with non- abnormalities at screening and check-in requires approval from the medical monitor and the sponsor's physician.
  6. Are predicted poor metabolizer CYP2D6 phenotypes. Note: Other protocol-specified inclusion/exclusion criteria may apply.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    14C-SEP-380135

    Participants receive a single oral administration of 14C-SEP-380135 on Day 1.

    Drug: 14C-SEP-380135

Interventions

  • Drug14C-SEP-380135

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Total Radioactivity Amount Excreted in Urine (Ae,u)

    Time frame: Up to Day 8

  2. Total Radioactivity Amount Excreted in Feces (Ae,f)

    Time frame: Up to Day 8

  3. Fraction of Dose Excreted in Urine (%fe,u)

    Time frame: Up to Day 8

  4. Fraction of Dose Excreted in Feces (%fe,f)

    Time frame: Up to Day 8

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of SEP-380135 and Metabolites

    Time frame: Up to Day 8

  2. Time for Cmax (tmax) of SEP-380135 and Metabolites

    Time frame: Up to Day 8

  3. Area Under the Concentration-Time Curve From Time Zero to the Last Observable Concentration at Time (AUCt) of SEP-380135 and Metabolites

    Time frame: Up to Day 8

  4. Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC∞) of SEP-380135 and Metabolites

    Time frame: Up to Day 8

  5. Elimination Half-Life (t1/2,z) of SEP-380135 and Metabolites

    Time frame: Up to Day 8

  6. Apparent Clearance of Drug From Plasma After Oral Administration (CL/F) of SEP-380135

    Time frame: Up to Day 8

  7. Apparent Clearance of Drug From Plasma After Oral Administration Adjusted for Body Weight (CL/F/BW) of SEP-380135

    Time frame: Up to Day 8

  8. Volume of Distribution Following Oral Administration (Vz/F) of SEP-380135

    Time frame: Up to Day 8

  9. Number of Participants with Adverse Events (AEs)

    Time frame: Up to Day 31

  10. Number of Participants with Potentially Clinically Significant Changes in Vital Signs

    Time frame: Upto Day 8

  11. Number of Participants With Potentially Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    Time frame: Upto Day 8

  12. Number of Participants With Potentially Clinically Significant Changes in Physical Examinations

    Time frame: Upto Day 8

  13. Number of Participants With Potentially Clinically Significant Changes in Clinical Laboratory Test Parameters

    Time frame: Upto Day 8

  14. Number of Participants With Incidence of Suicidal Ideation and Suicidal Behavior Using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Upto Day 8

07

Study locations

1 site
  • Celerion, Inc.
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No — Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2026, 1 month later.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 1 month is below that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Mar 2026 → Nov 2026, primary completion Apr 2026 → Dec 2026 and completion May 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 6, 2026
StartEst.
Nov 1, 2026was Mar 2026
Primary completionEst.
Dec 2, 2026was Apr 2026
CompletionEst.
Dec 2, 2026was May 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Mar 20, 2026→Nov 1, 2026
Oct 16, 2026
Primary completion
Apr 10, 2026→Dec 2, 2026
Oct 16, 2026
Study completion
May 3, 2026→Dec 2, 2026
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Mar 20, 2026→Nov 1, 2026
    Primary completion Apr 10, 2026→Dec 2, 2026
    Study completion May 3, 2026→Dec 2, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07455084
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Dec 2, 2026 (estimated)
Completion
Dec 2, 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Otsuka Call Center
Contact
Otsuka-ProfessionalServices@otsuka-us.com
844-687-8522

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion